Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TELA logo TELA
Upturn stock ratingUpturn stock rating
TELA logo

Tela Bio Inc (TELA)

Upturn stock ratingUpturn stock rating
$1.6
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TELA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5.4

1 Year Target Price $5.4

Analysts Price Target For last 52 week
$5.4 Target price
52w Low $0.86
Current$1.6
52w High $3.26

Analysis of Past Performance

Type Stock
Historic Profit -2.15%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 63.39M USD
Price to earnings Ratio -
1Y Target Price 5.4
Price to earnings Ratio -
1Y Target Price 5.4
Volume (30-day avg) 5
Beta 0.93
52 Weeks Range 0.86 - 3.26
Updated Date 08/15/2025
52 Weeks Range 0.86 - 3.26
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.06

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-11
When -
Estimate -0.18
Actual -0.22

Profitability

Profit Margin -54.12%
Operating Margin (TTM) -44.96%

Management Effectiveness

Return on Assets (TTM) -36.47%
Return on Equity (TTM) -676.41%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 70311304
Price to Sales(TTM) 0.84
Enterprise Value 70311304
Price to Sales(TTM) 0.84
Enterprise Value to Revenue 0.93
Enterprise Value to EBITDA -5.01
Shares Outstanding 39616400
Shares Floating 18693017
Shares Outstanding 39616400
Shares Floating 18693017
Percent Insiders 8.3
Percent Institutions 74.2

ai summary icon Upturn AI SWOT

Tela Bio Inc

stock logo

Company Overview

overview logo History and Background

Tela Bio, Inc. was founded in 2012 and is focused on developing and marketing regenerative tissue matrix products for soft tissue reconstruction. The company has grown through product development and commercialization of its OviTex and reinforced brands.

business area logo Core Business Areas

  • Surgical Reconstruction: This segment develops and sells surgical mesh products for hernia repair and abdominal wall reconstruction. Their OviTex Reinforced Tissue Matrix is a key product in this segment.
  • Reconstructive and Plastic Surgery: Offers products for breast reconstruction and other plastic surgery procedures, utilizing regenerative tissue matrix technology.

leadership logo Leadership and Structure

Tela Bio is led by Antony Koblish as President and CEO. The company has a typical corporate structure with departments for R&D, manufacturing, sales and marketing, and finance.

Top Products and Market Share

overview logo Key Offerings

  • OviTex Reinforced Tissue Matrix: OviTex is a reinforced tissue matrix used in hernia repair and abdominal wall reconstruction. While precise market share data is variable and depends on the specific sub-segment, Tela Bio is a significant player in the biosurgical mesh market. Competitors include BD (Becton Dickinson - BDX), Medtronic (MDT), and W.L. Gore & Associates.
  • Reinforced Brands (OviTex PRS, etc.): This is a range of reinforced brands which are variants of OviTex. Market share data and competitors are generally the same as OviTex but it serves the breast reconstruction market.

Market Dynamics

industry overview logo Industry Overview

The surgical mesh and regenerative medicine market is growing due to an aging population, increasing surgical procedures, and technological advancements. Key trends include minimally invasive surgery and the use of biologic materials.

Positioning

Tela Bio is positioned as an innovator in regenerative tissue matrices, focusing on improved patient outcomes and reduced complications compared to synthetic meshes. Their competitive advantage lies in their patented OviTex technology.

Total Addressable Market (TAM)

The global surgical mesh market is estimated to be billions of dollars. Tela Bio's positioning allows it to capture a growing share of this market, particularly in the biologic and reinforced mesh segments. Specific TAM estimates vary depending on the source and market definition.

Upturn SWOT Analysis

Strengths

  • Proprietary OviTex technology
  • Focus on regenerative medicine
  • Growing revenue and market share
  • Strong sales force dedicated to their field

Weaknesses

  • Reliance on a limited number of products
  • Need for continued innovation to maintain competitive edge
  • High marketing costs for market penetration

Opportunities

  • Expansion into new geographic markets
  • Development of new applications for OviTex technology
  • Strategic partnerships and acquisitions
  • Increase in the number of surgical procedures

Threats

  • Competition from larger medical device companies
  • Regulatory changes and increased scrutiny
  • Product liability lawsuits
  • Price pressures from healthcare providers

Competitors and Market Share

competitor logo Key Competitors

  • BDX
  • MDT
  • SYK

Competitive Landscape

Tela Bio's advantages include its proprietary technology and focus on regenerative medicine. Disadvantages include its smaller size and limited product portfolio compared to larger competitors.

Growth Trajectory and Initiatives

Historical Growth: Tela Bio has experienced significant revenue growth in recent years due to increased adoption of OviTex and reinforced brands.

Future Projections: Analysts expect continued revenue growth for Tela Bio, driven by expansion into new markets and product development. Profitability is expected to improve as the company scales.

Recent Initiatives: Recent initiatives include expanding the sales force, launching new OviTex products and entering new markets.

Summary

Tela Bio is a company with promising growth based on its regenerative medicine products, particularly OviTex. Its smaller size compared to its peers poses a potential risk. Successful market penetration and innovation will be key. Regulatory landscape and economic fluctuations require a cautious outlook.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Analyst Reports
  • Market Research Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary depending on the source. Please do your own research before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tela Bio Inc

Exchange NASDAQ
Headquaters Malvern, PA, United States
IPO Launch date 2019-11-08
Co-founder, CEO & Director Mr. Antony Koblish
Sector Healthcare
Industry Medical Devices
Full time employees 209
Full time employees 209

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.